Exclusive extracts from this 73-page-long report:
- Who are the key players?
The pharmaceutical industry remains relatively fragmented despite recent years' wave of consolidation that has seen big pharma groups focus on acquisitions to adapt to an increasingly challenging market environment. Mature-market players continue to rule the industry, with US, European and Japanese pharma groups occupying the industry's top spots. However, emerging market drug companies have gained global market share in recent years amid growing opportunities in their home markets. [...]
Groups analysed in this report include: Pfizer, Novartis, Roche, Merck & Co., Sanofi-Aventis, GlaxoSmithKline, Johnson&Johnson Pharmaceutical, AbbVie, Teva Pharmaceutical, and Bayer.
- What are the players' strategies?
Confronted with low levels of new drug approvals, the loss of patents for top-selling drugs, and a challenging market environment that is putting pressure on prices and sales, market leaders continue to focus primarily on innovation in new treatment areas as well as targeted acquisitions and partnerships to strengthen their operations. AbbVie for instance setg up an exclusive alliance with Voyager Therapeutics, a gene therapy company, to develop innovative therapies for severe neurological disorders, an area in which it sees great potential for the coming decade. Novartis also highlighted its focus on innovative gene therapy treatments by securing a US$ 9 billion buyout of US-based AveXis, while Takeda recently announced the $65bn purchase of Dublin-based Shire. […]
- What are the players' key growth and profitability drivers?
Sound revenue growth and high profitability from major players such as Bayer, AbbVie or Roche were the result of strong performances by these groups' key drug brands, newly-introduced treatments, and acquisitions. Conversely, leaders such as Novartis or Merck & Co saw sales slow or even decline as a result of increased price pressure, loss of key patents, and increased competition from generics. [...]